Posted by Michael Wonder on 05 Feb 2020
Greater support for kidney disease patients following key new medicines listing on PBS
3 February 2020 - There’s new hope for Australians living with chronic kidney disease, cystic fibrosis, and tumours of the midgut, thanks to new and amended medicines listings on the Pharmaceutical Benefits Scheme (PBS) from 1 February 2020.
There’s new hope for Australians living with chronic kidney disease, cystic fibrosis, and tumours of the midgut, thanks to new and amended medicines listings on the Pharmaceutical Benefits Scheme (PBS) from 1 February 2020.
Symdeko was listed on the PBS on 1 December 2019 for the treatment of cystic fibrosis, and will now be extended to ensure all patients with at least one residual function mutation in the CFTR gene have access to this medicine.
The Government will also extend the PBS listing of Sandostatin to patients with non‑functional neuroendocrine tumours of the midgut.
